Article: An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir

Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized 6 hours after overdosing with 24,000 mg of raltegravir in a suicide attempt. No serious adverse events occurred, although the plasma concentration of raltegravir at 18 hours after the overdose was 79,871.1 ng/mL. Raltegravir may be well-indicated for HIV patients at risk of overdosing.

Citing Articles

Were Additional Treatments Affecting Pharmacokinetics Administered after Raltegravir Overdosing?: Authors' Reply.

Hosoda T, Uehara Y, Naito T Intern Med. 2020; 59(10):1343.

PMID: 32074582 PMC: 7303453. DOI: 10.2169/internalmedicine.4328-19.

Were Additional Treatments Affecting the Pharmacokinetics Administered after Raltegravir Overdosing?.

Fukuchi T, Sugawara H Intern Med. 2020; 59(10):1341.

PMID: 32074580 PMC: 7303457. DOI: 10.2169/internalmedicine.4246-19.

References

1.

Blanch J, Corbella B, Garcia F, Parellada E, Gatell J . Manic syndrome associated with efavirenz overdose. Clin Infect Dis. 2001; 33(2):270-1. DOI: 10.1086/321828. View

2.

Zembower T, Gerzenshtein L, Coleman K, Palella Jr F . Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008; 22(11):1382-4. DOI: 10.1097/QAD.0b013e328303be40. View

3.

Yoshimoto E, Konishi M, Uno K, Nakagawa C, Yonekawa S, Kasahara K . [A case of acute renal failure involving high amounts of tenofovir after HAART start]. Kansenshogaku Zasshi. 2008; 82(6):650-3. DOI: 10.11150/kansenshogakuzasshi1970.82.650. View

4.

Reiss K, Bailey J, Pham P, Gallant J . Raltegravir-induced cerebellar ataxia. AIDS. 2010; 24(17):2757. DOI: 10.1097/QAD.0b013e32833fca42. View

5.

Krishna R, Rizk M, Larson P, Schulz V, Kesisoglou F, Pop R . Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir. Clin Pharmacol Drug Dev. 2017; 7(2):196-206. DOI: 10.1002/cpdd.358. View

6.

Krentz H, Kliewer G, Gill M . Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005; 6(2):99-106. DOI: 10.1111/j.1468-1293.2005.00271.x. View

7.

Iwamoto M, Wenning L, Petry A, Laethem M, De Smet M, Kost J . Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2007; 83(2):293-9. DOI: 10.1038/sj.clpt.6100281. View

8.

Bing E, Burnam M, Longshore D, Fleishman J, Sherbourne C, London A . Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001; 58(8):721-8. DOI: 10.1001/archpsyc.58.8.721. View

9.

Clifford D, Evans S, Yang Y, Acosta E, Ribaudo H, Gulick R . Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2010; 10(6):343-55. PMC: 2958039. DOI: 10.1310/hct1006-343. View

10.

Elliot E, Chirwa M, Boffito M . How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use. Curr Opin Infect Dis. 2016; 30(1):58-73. DOI: 10.1097/QCO.0000000000000327. View

An HIV-infected Patient with No Serious Adverse Events After Overdosing on Raltegravir